# Study of EMB-001 as a Potential Smoking Cessation Treatment

> **NCT04933916** · PHASE1,PHASE2 · TERMINATED · sponsor: **Embera NeuroTherapeutics, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Tobacco Use Disorder

## Interventions

- **DRUG:** EMB-001

## Key facts

- **NCT ID:** NCT04933916
- **Lead sponsor:** Embera NeuroTherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-10
- **Primary completion:** 2023-04-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2023-08-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04933916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04933916, "Study of EMB-001 as a Potential Smoking Cessation Treatment". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04933916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*